Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry

Health Services Research

Volumn 35, Issue 2, 2000, Pages 529-547

  Suh, Dong Churl ^a   Manning Jr , Willard G ^a   Schondelmeyer, Stephen ^a   Hadsall, Ronald S ^a  

^a NONE

Author keywords

Drug Price Competition and Patent Term Restoration Act; Multiple source drugs; Patent; Pharmaceutical industry; Price competition

Indexed keywords

DRUG;

COMPETITION; CONSUMER; DATA BASE; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; EXPIRATION DATE; MANAGED CARE; PATENT; PHARMACY; REVIEW;

DRUG COSTS; DRUG INDUSTRY; DRUGS, GENERIC; ECONOMIC COMPETITION; HUMANS; MODELS, ECONOMETRIC; PATENTS; REGRESSION ANALYSIS; UNITED STATES;

EID: 0034125928     PISSN: 00179124     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Bresnahan, T. F., and P. C. Reiss. 1990. "Entry in Monopoly Markets." Review of Economic Studies 57 (4): 531-53.
2. Caves, R. E., M. D. Whinston, and M. A. Hurwitz. 1991. "Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry." Brookings Papers on Economic Activity, 1-66. Brookings Institute.
3. Cocks, D. L., and J. R. Virts. 1974. "Pricing Behavior of the Ethical Pharmaceutical Industry." Journal of Business 47 (3): 347-62.
4. Flannery, E. J., and P. B. Hutt. 1985. "Balancing Competition and Patent Protection in the Drug Industry: The Drug Price Competition and Patent Term Restoration Act of 1984." Food Drug Cosmetic Law Journal 40 (3): 269-309.
5. Frank, R. G., and D. S. Salkever. 1992. "Pricing, Patent Loss and Market for Pharmaceuticals." Southern Economic Journal 59 (2): 165-79.
6. Grabowski, H. G., and J. M. Vernon. 1996. "Longer Patents for Increased Generic Competition in the U.S." PharmacoEconomics 10 (2, Supplement): 110-23.
7. _. 1992. "Brand Loyalty, Entry and Price Competition in Pharmaceuticals After the 1984 Drug Act." Journal of Law & Economics 35 (October): 331-50.
8. Greene, W. H. 1996. Econometric Analysis. Upper Saddle River, NJ: Prentice-Hall.
9. Hsiao, C. 1992. Analysis of Panel Data. New York: Press Syndicate of the Cambridge University Press.
10. Hurwitz, M. A., and R. E. Caves. 1988. "Persuasion or Information? Promotion and the Shares of Brand Name and Generic Pharmaceuticals." Journal of Law & Economics 31 (October): 299-320.
11. James, B. G. 1981. The Marketing of Generic Drugs. Fleet Street, London: Associated Business Press.
12. Lidstone, J., and T. Collier. 1987. Marketing Planning for the Pharmaceutical Industry. Brookfield, VT: Gower Publishing Company.
13. Lu, Z. J., and W. S. Comanor. 1998. "Strategic Pricing of New Pharmaceuticals." Review of Economics & Statistics 80 (1): 108-18.
14. Mansfield, E. 1962. "Entry, Gibrat's Law, Innovation and the Growth of Firms." American Economic Review 52 (5): 1023-51.
15. Reekie, W. D. 1978. "Price and Quality Competition in the United States Drug Industry." Journal of Industrial Economics 26 (3): 223-37.
16. _. 1975. The Economics of the Pharmaceutical Industry. London: Macmillan Press.
17. Rosenthal, R. W. 1980. "A Model in Which an Increase in the Number of Sellers Leads to a Higher Price." Econometrics 48 (6): 1575-79.
18. Santerre, R. E., and S. P. Neun. 1996. Health Economics: Theories, Insights, and Industry Studies. Chicago: Irwin.
19. Satterthwaite, M. A. 1979. "Consumer Information, Equilibrium Price, and the Number of Sellers." The Bell Journal of Economics 10 (2): 482-502.
20. Scherer, F. M. 1985. "Post-Patent Barriers to Entry in the Pharmaceutical Industry." Journal of Health Economics 4 (1): 83-87.
21. Schmalensee, R. 1982. "Product Differentiation Advantages of Pioneering Brands." The American Economic Review 72 (3): 349-65.
22. Schwartzman, D. 1979. "Pricing of Multiple-Source Drugs." In Issues in Pharmaceutical Economics, edited by R. I. Chien, pp. 97-100. Lexington, MA: D. C. Heath and Company.
23. _. 1976. Innovation in the Pharmaceutical Industry. Baltimore, MD: Johns Hopkins University.
24. Shacknai, J. 1985. "Trade Secrets Under the Drug Price Competition and Patent Term Restoration Act of 1984." Food Drug Cosmetic Law Journal 40 (3): 329-38.
25. Statman, M. 1981. "The Effect of Patent Expiration on the Market Position of Drugs." In Drugs and Health, edited by R. B. Helms, pp. 140-51. Washington DC: American Enterprise Institute for Public Policy Research.
26. Teeling-Smith, G. 1975. "The Canberra Hypothesis: The Economics of the Prescription Medicine Market." Presented to the Pharmaceutical Sciences Section of the Academy and New Zealand Association for the Advancement of Science, London.
27. Walker, H. D. 1971. Market Power and Price Levels in the Ethical Drug Industry. Indianapolis: Indiana University Press.
28. Yip, G. S. 1982. Barriers to Entry. Lexington, MA: Lexington Books.